Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Mindset disagrees with and denies the allegations set forth from Reunion.
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Proposed combination enhances Pfizer’s position as a leading company in oncology
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Twelve hospitals across India will be part of the network which will support the trial in India
Subscribe To Our Newsletter & Stay Updated
